It can be concluded that ALDH1A1 inhibition, targeting primarily leukemia stem cells, could be combined with drugs that target non-stem cells, with the aim to eradicate both quiescent and proliferating AML cell fractions. Here, ALDH1A1 is linked to leukemia.